{"id":380590,"date":"2020-11-13T01:03:18","date_gmt":"2020-11-13T06:03:18","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=380590"},"modified":"2020-11-13T01:03:18","modified_gmt":"2020-11-13T06:03:18","slug":"obseva-sa-to-present-at-jefferies-virtual-london-healthcare-conference-november-17-19-2020","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/obseva-sa-to-present-at-jefferies-virtual-london-healthcare-conference-november-17-19-2020\/","title":{"rendered":"ObsEva SA to present at Jefferies Virtual London Healthcare Conference, November 17 \u2013 19, 2020"},"content":{"rendered":"
\n

\n Geneva, Switzerland and Boston, MA \u2013 November 13, 2020<\/strong> \u2013 ObsEva SA (NASDAQ: OBSV \/ SIX: OBSN), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women\u2019s reproductive health today announced that Company Management will present an update on the Company and its pipeline at the 11th<\/sup> Annual Jefferies (Virtual) London Healthcare Conference, taking place November 17 – 19, 2020.<\/p>\n

ObsEva\u2019s presentation will take place on Wednesday November 18 at 12:55 p.m. Greenwich Mean Time (GMT).\u00a0 A live presentation link will be available under \u201cEvents Calendar\u201d in the investors section of ObsEva\u2019s website at www.ObsEva.com<\/u><\/a><\/p>\n

\n About ObsEva<\/strong>\n <\/p>\n

ObsEva is a biopharmaceutical company developing and commercializing novel therapies to improve women\u2019s reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on treating endometriosis, uterine fibroids, preterm labor, and improving ET outcomes following IVF. ObsEva is listed on the Nasdaq Global Select Market and is trading under the ticker symbol “OBSV” and on the SIX Swiss Exchange where it is trading under the ticker symbol \u201cOBSN\u201d. For more information, please visit www.ObsEva.com<\/a><\/u>.<\/p>\n

\n Cautionary Note Regarding Forward Looking Statements <\/strong>\n <\/p>\n

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “believe”, “expect”, “may”, “plan,” “potential,” “will,” and similar expressions, and are based on ObsEva\u2019s current beliefs and expectations. These forward-looking statements include expectations regarding the clinical development of ObsEva\u2019s product candidates. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the conduct of clinical trials, clinical development and related interactions with regulators, , ObsEva\u2019s reliance on third parties over which it may not always have full control, the impact of the novel coronavirus outbreak, and other risks and uncertainties that are described in the Risk Factors section of ObsEva\u2019s Annual Report on Form 20-F for the year ended December 31, 2019, the Risk Factors disclosed in ObsEva\u2019s Report on Form 6-K filed with the Securities and Exchange Commission (SEC) on November 5, 2020 and other filings ObsEva makes with the SEC. These documents are available on the Investors page of ObsEva\u2019s website at http:\/\/www.obseva.com<\/a><\/u>. Any forward-looking statements speak only as of the date of this press release and are based on information available to ObsEva as of the date of this release, and ObsEva assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.<\/p>\n

\n For further information, please contact: <\/strong>\n <\/p>\n

\n CEO Office contact<\/strong>
\n
Shauna Dillon
Shauna.dillon@<\/u>obseva<\/u>.ch<\/u><\/a>
+41 22 552 1550<\/p>\n

\u00a0<\/p>\n

\u00a0<\/p>\n

\u00a0<\/p>\n

\n Attachment<\/strong>\n <\/p>\n